Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06 déc. 2024 08h00 HE
|
Pacira BioSciences
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the...
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
03 déc. 2024 07h30 HE
|
Pacira BioSciences
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences,...
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
14 nov. 2024 10h05 HE
|
Pacira BioSciences
PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
12 nov. 2024 08h00 HE
|
Pacira BioSciences
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare...
Pacira BioSciences Reports Third Quarter 2024 Financial Results
06 nov. 2024 16h00 HE
|
Pacira BioSciences
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative,...
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
04 nov. 2024 08h00 HE
|
Pacira BioSciences
-- Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act -- -- Beginning January 1, 2025, providers can receive additional Medicare payment when they use...
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
30 oct. 2024 08h00 HE
|
Pacira BioSciences
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets...
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
21 oct. 2024 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
07 oct. 2024 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of...
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
03 oct. 2024 08h00 HE
|
Pacira BioSciences
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) --...